Recent News

• 08.05.2026 - MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.29.2026 - MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
• 07.28.2026 - MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
• 07.24.2026 - MannKind Announces $50 Million Private Placement
• 07.24.2026 - MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
• 06.23.2026 - MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
• 06.05.2026 - Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
• 06.03.2026 - MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
• 05.29.2026 - MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
• 05.29.2026 - MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

Recent Filings

• 08.07.2026 - 144 Report of proposed sale of securities
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 07.31.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.24.2026 - 8-K Current report
• 07.24.2026 - EX-99.1 EX-99.1
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities